Skip to main content

Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection

By January 8, 2018News
emergent-biosolution-logo

emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.

{iframe}http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-newsArticle&ID=2324838{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.